🎉 M&A multiples are live!
Check it out!

Apontis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Apontis Pharma and similar public comparables like Galapagos, Pharming, and Julphar.

Apontis Pharma Overview

About Apontis Pharma

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.


Founded

1946

HQ

Germany
Employees

137

Financials

LTM Revenue $54.3M

LTM EBITDA $4.8M

EV

$78.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Apontis Pharma Financials

Apontis Pharma has a last 12-month revenue of $54.3M and a last 12-month EBITDA of $4.8M.

In the most recent fiscal year, Apontis Pharma achieved revenue of $52.1M and an EBITDA of $3.8M.

Apontis Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Apontis Pharma valuation multiples based on analyst estimates

Apontis Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $39.7M $52.1M XXX XXX XXX
Gross Profit $37.6M $24.9M XXX XXX XXX
Gross Margin 95% 48% XXX XXX XXX
EBITDA -$13.8M $3.8M XXX XXX XXX
EBITDA Margin -35% 7% XXX XXX XXX
Net Profit $2.9M -$12.1M XXX XXX XXX
Net Margin 7% -23% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Apontis Pharma Stock Performance

As of April 15, 2025, Apontis Pharma's stock price is EUR 11 (or $11).

Apontis Pharma has current market cap of EUR 88.7M (or $95.3M), and EV of EUR 73.3M (or $78.7M).

See Apontis Pharma trading valuation data

Apontis Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$78.7M $95.3M XXX XXX XXX XXX $0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Apontis Pharma Valuation Multiples

As of April 15, 2025, Apontis Pharma has market cap of $95.3M and EV of $78.7M.

Apontis Pharma's trades at 1.4x LTM EV/Revenue multiple, and 16.4x LTM EBITDA.

Analysts estimate Apontis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Apontis Pharma and 10K+ public comps

Apontis Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $78.7M XXX XXX XXX
EV/Revenue 1.5x XXX XXX XXX
EV/EBITDA 20.6x XXX XXX XXX
P/E 117.7x XXX XXX XXX
P/E/Growth 0.6x XXX XXX XXX
EV/FCF -14.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Apontis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Apontis Pharma Valuation Multiples

Apontis Pharma's NTM/LTM revenue growth is 16%

Apontis Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Apontis Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Apontis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Apontis Pharma and other 10K+ public comps

Apontis Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 31% XXX XXX XXX XXX
EBITDA Margin 7% XXX XXX XXX XXX
EBITDA Growth -128% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 23% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 11% XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 55% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Apontis Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Apontis Pharma M&A and Investment Activity

Apontis Pharma acquired  XXX companies to date.

Last acquisition by Apontis Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Apontis Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Apontis Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Apontis Pharma

When was Apontis Pharma founded? Apontis Pharma was founded in 1946.
Where is Apontis Pharma headquartered? Apontis Pharma is headquartered in Germany.
How many employees does Apontis Pharma have? As of today, Apontis Pharma has 137 employees.
Is Apontis Pharma publicy listed? Yes, Apontis Pharma is a public company listed on FRA.
What is the stock symbol of Apontis Pharma? Apontis Pharma trades under APPH ticker.
When did Apontis Pharma go public? Apontis Pharma went public in 2021.
Who are competitors of Apontis Pharma? Similar companies to Apontis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Apontis Pharma? Apontis Pharma's current market cap is $95.3M
What is the current revenue of Apontis Pharma? Apontis Pharma's last 12-month revenue is $54.3M.
What is the current EBITDA of Apontis Pharma? Apontis Pharma's last 12-month EBITDA is $4.8M.
What is the current EV/Revenue multiple of Apontis Pharma? Current revenue multiple of Apontis Pharma is 1.4x.
What is the current EV/EBITDA multiple of Apontis Pharma? Current EBITDA multiple of Apontis Pharma is 16.4x.
What is the current revenue growth of Apontis Pharma? Apontis Pharma revenue growth between 2023 and 2024 was 31%.
Is Apontis Pharma profitable? Yes, Apontis Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.